1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global - Adult Vaccines Market & Company Analysis to 2020

Global - Adult Vaccines Market & Company Analysis to 2020

  • May 2015
  • -
  • Igate Research
  • -
  • 232 pages

Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continues to be one of the growing segment for pharmaceutical companies. The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 7% over the next five years. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines are the most popular and accepted vaccination amongst adults. It accounted for maximum share of adult vaccines market in 2014. The vaccinations for hepatitis is the second most popular vaccines in 2014. The HPV/Cervical cancer vaccines and pneumococcal vaccines stands at third and fourth spots respectively in adult vaccines market. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.


Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquires Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second spot in the adult vaccines market. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer and Novartis is at the fourth and fifth position respectively in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in influenza vaccine landscape, while in the cervical cancer market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japan’s adult vaccines market share is expected to remain flat during the forecasting period. South America and India are competing closely with each other to get the maximum share of the adult vaccines market pie.

iGATE RESEARCH report entitled “Global - Adult Vaccines Market & Company Analysis to 2020” is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

The 9 Diseases covered in the report are analyzed from four viewpoints:

1. Adult Vaccines Market (2007 - 2020)
2. Number of Adults Vaccinated (2007 - 2020)
3. Number of Doses (2007 - 2020)
4. Company Sales Share (2010 - 2020)

The 6 Company covered in the report are analyzed from two viewpoints:

1. Disease Wise - Adult Vaccines Sales (2007 - 2020)
2. Strategic Alliances

The 8 Region covered in the report are analyzed from one viewpoint:

1. Adult Vaccines Market (2011 - 2020)

Global Adult Vaccines Market, Number of Adults Vaccinated and Doses - Disease Wise Analysis to 2020 (9 Disease Analysed)

1. Influenza
2. Cervical Cancer
3. Zoster Shingles
4. Pneumococcal
5. Meningococcal
6. MMRV
7. Hepatitis
8. DTP
9. Travel and Miscellaneous

Global Adult Vaccines Market - Company Analysis to 2020 (6 Company Analysed)

1. GlaxoSmithKline
2. Sanofi Pasteur
3. Merck
4. Novartis
5. Pfizer
6. Other Companies

Global Adult Vaccines Market - Regional Distribution to 2020 (8 Region Analysed)

1. United States
2. North America/Caribbean
3. South America
4. Europe
5. Japan
6. India
7. China
8. Rest of the World

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table Of Contents

Global - Adult Vaccines Market and Company Analysis to 2020
1. Executive Summary

2. Global - Adult Vaccines Analysis and Forecast (2007 - 2020)
2.1 Global Adult Vaccines Market and Forecast
2.2 Global Adult Vaccines - Number of Adults Vaccinated and Forecast

3. Global Adult Vaccine Market Share Analysis and Forecast (2010 - 2020)
3.1 Global Adult Vaccines - Disease Wise Adults Vaccinated Share and Forecast
3.2 Global Adult Vaccines - Disease Wise Market Share and Forecast
3.3 Global Adult Vaccines - Company Wise Market Share and Forecast
3.4 Companies Adult Vaccines - Disease Wise Sales Share and Forecast
3.4.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share and Forecast
3.4.2 Sanofi Pasteur - Adult Vaccines Sales Share and Forecast
3.4.3 Merck - Adult Vaccines Sales Share and Forecast
3.4.4 Novartis - Adult Vaccines Sales Share and Forecast
3.5 Adult Vaccine Disease Wise Market - Company Share and Forecast
3.5.1 Influenza Adult Vaccines - Company Market Share and Forecast
3.5.2 Cervical Cancer/HPV Adult Vaccines - Company Market Share and Forecast
3.5.3 Hepatitis Adult Vaccines - Company Market Share and Forecast
3.5.4 Pneumococcal Adult Vaccines - Company Market Share and Forecast
3.5.5 Meningococcal Adult Vaccines - Company Market Share and Forecast
3.5.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines - Company Market Share and Forecast
3.6 Global Adult Vaccines Market - Region Wise Share and Forecast

4. Global Adult Vaccine Market - Disease Wise Analysis
4.1 Influenza - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.1.1 Influenza - Adult Vaccine Market and Forecast
4.1.2 Influenza - Number of Adults Vaccinated and Forecast
4.1.3 Influenza - Number of Vaccines Doses and Forecast
4.2 Cervical Cancer/ HPV - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.2.1 Cervical Cancer/ HPV - Adult Vaccine Market and Forecast
4.2.2 Cervical Cancer/ HPV - Number of Adults Vaccinated and Forecast
4.2.3 Cervical Cancer/ HPV - Number of Vaccines Doses and Forecast
4.3 Zoster Shingles - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.3.1 Zoster Shingles - Adult Vaccine Market and Forecast
4.3.2 Zoster Shingles - Number of Adults Vaccinated and Forecast
4.3.3 Zoster Shingles - Number of Vaccines Doses and Forecast
4.4 Pneumococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.4.1 Pneumococcal - Adult Vaccine Market and Forecast
4.4.2 Pneumococcal - Number of Adults Vaccinated and Forecast
4.4.3 Pneumococcal - Number of Vaccines Doses and Forecast
4.5 Meningococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.5.1 Meningococcal - Adult Vaccine Market and Forecast
4.5.2 Meningococcal - Number of Adults Vaccinated and Forecast
4.5.3 Meningococcal - Number of Vaccines Doses and Forecast
4.6 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.6.1 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Market and Forecast
4.6.2 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Adults Vaccinated and Forecast
4.6.3 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Vaccines Doses and Forecast
4.7 Hepatitis - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.7.1 Hepatitis - Adult Vaccine Market and Forecast
4.7.2 Hepatitis - Number of Adults Vaccinated and Forecast
4.7.3 Hepatitis - Number of Vaccines Doses and Forecast
4.8 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.8.1 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Market and Forecast
4.8.2 Diphtheria, Tetanus, Pertussis (DTP) - Number of Adults Vaccinated and Forecast
4.8.3 Diphtheria, Tetanus, Pertussis (DTP) - Number of Vaccines Doses and Forecast
4.9 Travel and Miscellaneous - Adult Vaccine Analysis and Forecast (2007 - 2020)
5. Global Adult Vaccine Market - Company Analysis and Strategic Alliances

5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales and Forecast
5.1.2 Strategic Alliances of GlaxoSmithKline (GSK)
5.2 Sanofi Pasteur
5.2.1 Sanofi Pasteur Vaccines Sales and Forecast
5.2.2 Strategic Alliances of Sanofi Pasteur
5.3 Merck
5.3.1 Merck Vaccines Sales and Forecast
5.3.2 Strategic Alliances of Merck
5.4 Novartis
5.4.1 Novartis Vaccines Sales and Forecast
5.4.2 Strategic Alliances of Novartis
5.5 Pfizer
5.5.1 Pfizer Adult Vaccines Sales and Forecast
5.5.2 Strategic Alliances of Pfizer
5.6 Other Companies Sales and Forecast

6. Global Adult Vaccine - Disease Wise Company Sales and Forecast (2007 - 2020)
6.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales and Forecast
6.1.1 GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales and Forecast
6.1.2 GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.1.3 GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales and Forecast
6.1.4 GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales and Forecast
6.2 Sanofi Pasteur - Adult Vaccines Sales and Forecast
6.2.1 Sanofi Pasteur - Influenza Adult Vaccines Sales and Forecast
6.2.2 Sanofi Pasteur - DTP Adult Vaccines Sales and Forecast
6.2.3 Sanofi Pasteur - Meningococcal Adult Vaccines Sales and Forecast
6.3 Merck - Adult Vaccines Sales and Forecast
6.3.1 Merck/CSL - Influenza Adult Vaccines Sales and Forecast
6.3.2 Merck - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.3.3 Merck - Zoster Shingles Adult Vaccines Sales and Forecast
6.3.4 Merck - Pneumococcal Adult Vaccines Sales and Forecast
6.3.5 Merck - MMRV Adult Vaccines Sales and Forecast
6.3.6 Merck - Hepatitis Adult Vaccines Sales and Forecast
6.4 Novartis - Adult Vaccines Sales and Forecast
6.4.1 Novartis - Influenza Adult Vaccines Sales and Forecast
6.4.2 Novartis - Meningococcal Adult Vaccines Sales and Forecast
6.5 Pfizer - Adult Vaccines Sales and Forecast
6.5.1 Pfizer - Pneumococcal Adult Vaccines Sales and Forecast

7. Global Adult Vaccine Market - Regional Distribution (2011 - 2020)

7.1 United States - Adult Vaccine Market and Forecast
7.2 North America/Caribbean - Adult Vaccine Market and Forecast
7.3 South America - Adult Vaccine Market and Forecast
7.4 Europe - Adult Vaccine Market and Forecast
7.5 Japan - Adult Vaccine Market and Forecast
7.6 India - Adult Vaccine Market and Forecast
7.7 China - Adult Vaccine Market and Forecast
7.8 Rest of the World (ROW) - Adult Vaccine Market and Forecast

8. Major Vaccine Related Acquisitions (2005-2015)

9. Adult Vaccines Market - Driving Factors

9.1 GAVI Model Fuelling Vaccine Manufacturers
9.1.1 The Partnership Model
9.1.2 The Business Model
9.2 Global Immunization Vision and Strategy (GIVS)
9.3 Growing Vaccine Availability in United States
9.4 The Vaccine Injury Compensation Program
9.5 The Vaccine Safety Data link Project
9.6 Transformation of Vaccine Technologies
9.7 Global Vaccine Action Plan by WHO (2011 - 2020)
9.8 Continuous Focus on Effective Communication Strategies
10. Adult Vaccines Market - Challenges
10.1 Hurdles to Optimal use of Licensed Vaccines
10.1.1 Technical Obstacles
10.1.2 Economic obstacles
10.1.3 Cultural Obstacles
10.2 Shortening the Timeline for Vaccine Development
10.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
10.3.1 Legal Obstacles
10.3.2 General Technical Barriers
10.3.3 Economic Barriers
10.3.4 Regulatory Barriers
10.4 Refusal/Resistance to Vaccination
10.5 Vaccine Adverse Event Reporting System
10.6 Vaccine Shortages and Delays
10.7 Obstacles in Vaccine Research and Development
10.8 Barriers to New Entrants in the Vaccines Market


List of Figures:

Figure 2 1: Global - Adult Vaccines Market (Million US$), 2007 - 2014
Figure 2 2: Global - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 2 3: Global - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 2 4: Global - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 3 1: Global Adult Vaccines - Company Wise Market Share (Percent), 2010 - 2014
Figure 3 2: Global Adult Vaccines - Forecast for Company Wise Market Share (Percent), 2015 - 2020
Figure 3 3: GlaxoSmithKline (GSK) - Adult Vaccines Sales Share (Percent), 2007 - 2014
Figure 3 4: GlaxoSmithKline (GSK) - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 5: Sanofi Pasteur - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 6: Sanofi Pasteur - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 7: Merck - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 8: Merck - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 9: Novartis - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 10: Novartis* - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 11: Influenza Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 12: Influenza Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 13: Cervical Cancer/HPV Adult Vaccines - Company Market Share (Percent), 2007 - 2014
Figure 3 14: Cervical Cancer/HPV Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 15: Hepatitis Adult Vaccines - Company Market Share (Percent), 2008 - 2014
Figure 3 16: Hepatitis Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 17: Pneumococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 18: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 19: Meningococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 20: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 21: DTP Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 22: DTP Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 23: Region Wise - Adult Vaccines Market Share (Percent), 2011 - 2014
Figure 3 24: Region Wise - Forecast for Adult Vaccines Market Share (Percent), 2015 - 2020
Figure 4 1: Influenza - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 2: Influenza - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 3: Influenza - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 4: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 5: Influenza - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 6: Influenza - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 7: Cervical Cancer/ HPV - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 8: Cervical Cancer/ HPV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 9: Cervical Cancer/ HPV - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 10: Cervical Cancer/ HPV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 11: Cervical Cancer/ HPV - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 12: Cervical Cancer/ HPV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 13: Zoster Shingles - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 14: Zoster Shingles - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 15: Zoster Shingles - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 16: Zoster Shingles - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 17: Zoster Shingles - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 18: Zoster Shingles - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 19: Pneumococcal - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 20: Pneumococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 21: Pneumococcal - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 22: Pneumococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 23: Pneumococcal - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 24: Pneumococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 25: Meningococcal - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 26: Meningococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 27: Meningococcal - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 28: Meningococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 29: Meningococcal - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 30: Meningococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 31: MMRV - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 32: MMRV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 33: MMRV - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 34: MMRV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 35: MMRV - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 36: MMRV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 37: Hepatitis - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 39: Hepatitis - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 40: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 41: Hepatitis - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 42: Hepatitis - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 43: DTP - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 44: DTP - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 45: DTP - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 46: DTP - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 47: DTP - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 48: DTP - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 49: Travel and Miscellaneous - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 50: Travel and Miscellaneous - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 5 1: GlaxoSmithKline (GSK) - Adult Vaccine Sales (Million US$), 2007 - 2014
Figure 5 2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 3: Sanofi Pasteur - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 4: Sanofi Pasteur - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 5: Sanofi Pasteur - Pipeline Vaccines candidates (Phase III), February 2015
Figure 5 6: Sanofi Pasteur - Pipeline Vaccines candidates (Phase II), February 2015
Figure 5 7: Sanofi Pasteur - Pipeline Vaccines candidates (Phase I), February 2015
Figure 5 8: Merck - Adult Vaccine Sales (Million US$), 2007 - 2014
Figure 5 9: Merck - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 10: Novartis - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 11: Novartis* - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 12: Pfizer - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 13: Pfizer - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 14: Other Companies - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 15: Other Companies - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 6 1: GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 2: GlaxoSmithKline (GSK) - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 3: GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 4: GlaxoSmithKline (GSK) - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 5: GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 6: GlaxoSmithKline (GSK) - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 7: GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 8: GlaxoSmithKline (GSK) - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 9: Sanofi Pasteur - Influenza Adult Vaccines Sales (Million US$), 2009 - 2014
Figure 6 10: Sanofi Pasteur - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 11: Sanofi Pasteur - DTP Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 12: Sanofi Pasteur - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 13: Sanofi Pasteur - Meningococcal Adult Vaccines Sales (Million US$), 2009 - 2014
Figure 6 14: Sanofi Pasteur - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 15: Merck/CSL - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 16: Merck/CSL - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 17: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 18: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 19: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 20: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 21: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 22: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 23: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 24: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 25: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 26: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 27: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 28: Novartis* - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 29: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 30: GSK (Novartis) - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 31: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 32: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 7 1: United States - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 2: United States - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 5: South America - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 6: South America - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 7: Europe - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 8: Europe - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 9: Japan - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 10: Japan - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 11: India - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 12: India - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 13: China - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 14: China - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 15: ROW - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 16: ROW - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 9 1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012


List of Tables:

Table 3 1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2014
Table 3 2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2015 - 2020
Table 3 3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2014
Table 3 4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2015 - 2020
Table 8 1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)
Table 9 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 9 2: Global Goal-Level Indicators, 2015 and 2020
Table 9 3: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations


















Figure 6 17: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 18: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 19: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 20: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 21: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 22: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 23: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 24: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 25: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 26: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 27: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 28: Novartis* - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 29: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 30: GSK (Novartis) - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 31: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 32: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 7 1: United States - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 2: United States - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 5: South America - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 6: South America - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 7: Europe - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 8: Europe - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 9: Japan - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 10: Japan - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 11: India - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 12: India - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 13: China - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 14: China - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 15: ROW - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 16: ROW - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 9 1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012


List of Tables:

Table 3 1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2014
Table 3 2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2015 - 2020
Table 3 3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2014
Table 3 4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2015 - 2020
Table 8 1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)
Table 9 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 9 2: Global Goal-Level Indicators, 2015 and 2020
Table 9 3: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global - Adult Vaccines Market, Company Analysis and Forecast to 2021

Global - Adult Vaccines Market, Company Analysis and Forecast to 2021

  • $ 1490
  • Industry report
  • August 2016
  • by Igate Research

The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 6% over the next five years. Adults are as likely as children to die from diseases that they ...

Global Preventive Vaccines Market- Trends and Forecasts (2016 - 2021)

Global Preventive Vaccines Market- Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The global preventive vaccines market accounted for a value of USD 27.6 billion in 2015 and is expected to reach USD 55 billion by 2021, growing at a CAGR of 12.4% during the forecast period from 2016 ...

Global Prophylactic Human Vaccines Industry

Global Prophylactic Human Vaccines Industry

  • $ 4950
  • Industry report
  • July 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Prophylactic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines. The report ...

Vaccines: The World Market

March 2016 $ 4200

Vaccines Markets In China

March 2016 $ 4000

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.